559 related articles for article (PubMed ID: 32598305)
21. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection.
Verdecchia P; Cavallini C; Spanevello A; Angeli F
Eur J Intern Med; 2020 Jun; 76():14-20. PubMed ID: 32336612
[TBL] [Abstract][Full Text] [Related]
22. Comparative ACE2 variation and primate COVID-19 risk.
Melin AD; Janiak MC; Marrone F; Arora PS; Higham JP
Commun Biol; 2020 Oct; 3(1):641. PubMed ID: 33110195
[TBL] [Abstract][Full Text] [Related]
23. Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart.
Liu H; Gai S; Wang X; Zeng J; Sun C; Zhao Y; Zheng Z
Cardiovasc Res; 2020 Aug; 116(10):1733-1741. PubMed ID: 32638018
[TBL] [Abstract][Full Text] [Related]
24. Angiotensin-Converting Enzyme Gene Polymorphism and Severe Lung Injury in Patients with Coronavirus Disease 2019.
Zheng H; Cao JJ
Am J Pathol; 2020 Oct; 190(10):2013-2017. PubMed ID: 32735889
[TBL] [Abstract][Full Text] [Related]
25. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
26. The Lung Macrophage in SARS-CoV-2 Infection: A Friend or a Foe?
Abassi Z; Knaney Y; Karram T; Heyman SN
Front Immunol; 2020; 11():1312. PubMed ID: 32582222
[TBL] [Abstract][Full Text] [Related]
27. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2.
Chan KK; Dorosky D; Sharma P; Abbasi SA; Dye JM; Kranz DM; Herbert AS; Procko E
Science; 2020 Sep; 369(6508):1261-1265. PubMed ID: 32753553
[TBL] [Abstract][Full Text] [Related]
28. Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor.
Yang J; Petitjean SJL; Koehler M; Zhang Q; Dumitru AC; Chen W; Derclaye S; Vincent SP; Soumillion P; Alsteens D
Nat Commun; 2020 Sep; 11(1):4541. PubMed ID: 32917884
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2.
Monteil V; Kwon H; Prado P; Hagelkrüys A; Wimmer RA; Stahl M; Leopoldi A; Garreta E; Hurtado Del Pozo C; Prosper F; Romero JP; Wirnsberger G; Zhang H; Slutsky AS; Conder R; Montserrat N; Mirazimi A; Penninger JM
Cell; 2020 May; 181(4):905-913.e7. PubMed ID: 32333836
[TBL] [Abstract][Full Text] [Related]
30. Biological plausibility for interactions between dietary fat, resveratrol,
Horne JR; Vohl MC
Am J Physiol Endocrinol Metab; 2020 May; 318(5):E830-E833. PubMed ID: 32310688
[TBL] [Abstract][Full Text] [Related]
31. Light and corona: guided-wave readout for coronavirus spike protein-host-receptor binding.
Fedotov IV; Yi Z; Voronin AA; Svidzinsky AA; Sower K; Liu X; Vlasova E; Peng T; Liu X; Moiseev SA; Belousov VV; Sokolov AV; Scully MO; Zheltikov AM
Opt Lett; 2020 Oct; 45(19):5428-5431. PubMed ID: 33001920
[TBL] [Abstract][Full Text] [Related]
32. Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting.
Sharifkashani S; Bafrani MA; Khaboushan AS; Pirzadeh M; Kheirandish A; Yavarpour Bali H; Hessami A; Saghazadeh A; Rezaei N
Eur J Pharmacol; 2020 Oct; 884():173455. PubMed ID: 32745604
[TBL] [Abstract][Full Text] [Related]
33. Alternative splicing of ACE2 possibly generates variants that may limit the entry of SARS-CoV-2: a potential therapeutic approach using SSOs.
Rehman SU; Tabish M
Clin Sci (Lond); 2020 May; 134(10):1143-1150. PubMed ID: 32442315
[TBL] [Abstract][Full Text] [Related]
34. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses.
Letko M; Marzi A; Munster V
Nat Microbiol; 2020 Apr; 5(4):562-569. PubMed ID: 32094589
[TBL] [Abstract][Full Text] [Related]
35. ACE2 (Angiotensin-Converting Enzyme 2) in Cardiopulmonary Diseases: Ramifications for the Control of SARS-CoV-2.
Sharma RK; Stevens BR; Obukhov AG; Grant MB; Oudit GY; Li Q; Richards EM; Pepine CJ; Raizada MK
Hypertension; 2020 Sep; 76(3):651-661. PubMed ID: 32783758
[TBL] [Abstract][Full Text] [Related]
36. Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications.
Banu N; Panikar SS; Leal LR; Leal AR
Life Sci; 2020 Sep; 256():117905. PubMed ID: 32504757
[TBL] [Abstract][Full Text] [Related]
37. Host Polymorphisms May Impact SARS-CoV-2 Infectivity.
Brest P; Refae S; Mograbi B; Hofman P; Milano G
Trends Genet; 2020 Nov; 36(11):813-815. PubMed ID: 32828550
[TBL] [Abstract][Full Text] [Related]
38. Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome.
Gómez J; Albaiceta GM; García-Clemente M; López-Larrea C; Amado-Rodríguez L; Lopez-Alonso I; Hermida T; Enriquez AI; Herrero P; Melón S; Alvarez-Argüelles ME; Boga JA; Rojo-Alba S; Cuesta-Llavona E; Alvarez V; Lorca R; Coto E
Gene; 2020 Dec; 762():145102. PubMed ID: 32882331
[TBL] [Abstract][Full Text] [Related]
39. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome.
Devaux CA; Rolain JM; Raoult D
J Microbiol Immunol Infect; 2020 Jun; 53(3):425-435. PubMed ID: 32414646
[TBL] [Abstract][Full Text] [Related]
40. Renin-angiotensin system at the heart of COVID-19 pandemic.
Alifano M; Alifano P; Forgez P; Iannelli A
Biochimie; 2020 Jul; 174():30-33. PubMed ID: 32305506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
